ICR

Multi Vessel Disease in STEMI

Multi Vessel Disease in STEMI

OptoWire: how performance and accuracy make the difference in physiology-guided PCI

Wednesday 17th June 2020
@ 16:00 (BST)

Reserve Your Seat for this event.

 

This engaging webinar will present a complex PCI clinical case of a STEMI patient with coronary Multi Vessel Disease where OptoWire – OpSens' pressure guidewire – makes the physiology-guided procedure easy and reliable. The programme aims to address the needs of operators in this clinical setting and describe how OptoWire technological enhancements vs the most used physiology wires in the market translate in practical advantages providing physicians with the most reliable support during the procedure.

The case will be presented by Prof Jacques Monsegu (GHM Grenoble, FR). Prof Pim Tonino (Eindhoven, NL) will facilitate the debate and the live audience Q&A.

  • Learn about the current limitations in performing a full physiology-guided assessment in patients with multi-vessel disease
  • Discover the importance of durability in pressure guidewire technology to perform complex assessments last and easy without compromising accuracy of the measurement
  • Debate on the different decision-making strategies and the importance of a reliable diagnostic tool
  • 5 mins - Introductions and background
  • 12 mins - Case presentation
  • 15 mins - Discussion and live Q&A
  • Interventional cardiologists doing more than 50 physiology-guided PCI per year
  • Believers either in resting physiology (NHPR) and/or in hyperemic physiology (FFR)

 

Prof Pim Tonino
Catharina Hospital, Eindhoven, The Netherlands

 

Prof Jacques Monsegu
Groupe Hospitalier Mutualiste de Grenoble, France

 

 
 

This webinar is supported by:

Diagnostic Angiograms and Percutaneous Coronary Interventions in Pregnancy

Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Many profound physiological changes take place in the cardiovascular system during pregnancy to meet the increased metabolic demands of both the mother and foetus.

Transcatheter aortic valve replacement update in bicuspid aortic valve disease

Transcatheter aortic valve replacement update in bicuspid aortic valve disease

Thursday 04th June 2020
@ 17:00 (BST)

Reserve Your Seat for this event.

 

‘Transcatheter aortic valve replacement update in bicuspid aortic valve disease’ brings together four international opinion leaders to comprehensively review the latest clinical evidence, evaluate recent trial outcomes, address patient and device selection, and provide practical insight through case reviews.

Designed to best support both cardiologists and surgeons, this engaging one-hour educational programme will be further enhanced through a live Q&A session, to help address some of the most pertinent and challenging questions in clinical practice.

  • Describe the latest data in bicuspid valve disease and understand the classifications
  • Critically evaluate clinical trial data in TAVR in low-risk bicuspid patients
  • Review implant techniques and device considerations for bicuspid patients

This programme has been formulated to best support the learnings of cardiologists and surgeons globally.

  • Welcome, introduction to the topic – Prof Van Mieghem, Chair (6 mins)
  • TAVR in low risk bicuspid patients: critical review of the clinical evidence – Dr Ramlawi (12 mins)
  • Implant techniques and device selections for bicuspid patients – Presentation by Dr Tchetche (12 mins)
  • TAVR in bicuspid patients: case reviews – Prof Zahr (12 mins)
  • Discussion and live Q&A – All, moderated by Prof Van Mieghem (18 mins)

 

Prof Nicolas M Van Mieghem
Thoraxcenter, Erasmus MC, Rotterdam, NL

 

Dr Basel Ramlawi
Heart & Vascular Center, Valley Health System, Virginia, US

 

Dr Didier Tchetche
Clinique Pasteur, Toulouse, FR

 

Prof Firas Zahr
Oregon Health and Science University, US

 

 
 

This virtual programme is supported by an unrestricted educational grant from:

Precision Medicine in Interventional Cardiology

Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Evidence-based medicine is the foundation of contemporary clinical practice and results in better clinical outcomes than experience-based medicine.1 Meta-analyses of homogenous randomised controlled clinical trials are the pinnacle of evidence-based medicine and the backbone of the highest recommendations in clinical guidelines.

Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status

Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Transcatheter aortic valve implantation (TAVI) is a valuable treatment option for patients with severe symptomatic aortic stenosis.1 Its use is supported by the results of multiple randomised controlled trials (RCTs) exploring the entire surgical risk spectrum, including inoperable, high-risk, intermediate risk and low risk patients.2–8 TAVI is associated with a small but not negligible complication rate that exceeds that observed for percutaneous coronary intervention by approxima

An Extended Statement by the British Cardiovascular Intervention Society President Regarding the COVID-19 Pandemic

Open access
This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Further to the statement that was released to members of the British Cardiovascular Intervention Society (BCIS) on 17 March 2020 about the coronavirus disease 2019 (COVID-19) pandemic,1 I have now been offered this opportunity to expand and update on the advice and comments in that original document in the light of recent developments, particularly with regard to personal protective equipment (PPE) and our recent guidance about cath lab procedures.